(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -11.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Sarepta Therapeutics's revenue in 2026 is $1,974,344,000.On average, 27 Wall Street analysts forecast SRPT's revenue for 2026 to be $197,733,783,312, with the lowest SRPT revenue forecast at $175,763,362,944, and the highest SRPT revenue forecast at $227,943,111,318. On average, 26 Wall Street analysts forecast SRPT's revenue for 2027 to be $152,736,672,366, with the lowest SRPT revenue forecast at $91,157,175,393, and the highest SRPT revenue forecast at $196,783,140,123.
In 2028, SRPT is forecast to generate $154,426,704,702 in revenue, with the lowest revenue forecast at $124,111,749,675 and the highest revenue forecast at $188,755,486,527.